| pubmed-article:17989720 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C0023470 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C0026986 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C1533699 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C1439292 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C1524062 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C1705576 | lld:lifeskim |
| pubmed-article:17989720 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17989720 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:17989720 | pubmed:dateCreated | 2008-2-13 | lld:pubmed |
| pubmed-article:17989720 | pubmed:abstractText | We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment failure or death within 30 days. 'Response' was engraftment and remission (CR) on day +30. We sought to determine the GO dose (2, 4 or 6 mg m(-2)) giving the best trade-off between toxicity and response. All patients were not candidates for myeloablative regimens. Treatment plan: GO (day -12), fludarabine 30 mg m(-2) (days -5 to -2), melphalan 140 mg m(-2) (day -2) and HSCT (day 0). GVHD prophylaxis was tacrolimus and mini-methotrexate. Diagnoses were AML (n=47), MDS (n=4) or CML (n=1). Median age was 53 years (range, 13-72). All but three patients were not in CR. Donors were related (n=33) or unrelated (n=19). Toxicity and response rates at 4 mg m(-2) were 50% (n=4) and 50% (n=4). GO dose was de-escalated to 2 mg m(-2): 18% had toxicity (n=8) and 82% responded (n=36). 100-day TRM was 15%; one patient had reversible hepatic VOD. Median follow-up was 37 months. Median event-free and overall survival was 6 and 11 months. GO 2 mg m(-2) can be safely added to fludarabine/melphalan, and this regimen merits further evaluation. | lld:pubmed |
| pubmed-article:17989720 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17989720 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17989720 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17989720 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17989720 | pubmed:issn | 1476-5551 | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:CookJ DJD | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:McCormickGG | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:ChanK WKW | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:WangXX | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:ShpallE JEJ | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:ChamplinR ERE | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:AnderssonB... | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:KhouriII | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:GiraltSS | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:ThallP FPF | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:JabbourEE | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:AnderliniPP | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:KebriaeiPP | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:QazilbashMM | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:CourielDD | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:de LimaMM | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:MartinT... | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:HosinoKK | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:PatahP APA | lld:pubmed |
| pubmed-article:17989720 | pubmed:author | pubmed-author:CalderaZZ | lld:pubmed |
| pubmed-article:17989720 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17989720 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:17989720 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17989720 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17989720 | pubmed:pagination | 258-64 | lld:pubmed |
| pubmed-article:17989720 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:meshHeading | pubmed-meshheading:17989720... | lld:pubmed |
| pubmed-article:17989720 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17989720 | pubmed:articleTitle | Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. | lld:pubmed |
| pubmed-article:17989720 | pubmed:affiliation | Department of Stem Cell Transplantation and Cell Therapy, U.T.M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. mdelima@mdanderson.org | lld:pubmed |
| pubmed-article:17989720 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17989720 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:17989720 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
